Form 4: Neurocrine Biosciences Director Reports Stock Transactions

Director Richard F. Pops reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Summary

• Richard F. Pops, a director of Neurocrine Biosciences, reported transactions involving the company's stock.
• On May 22, 2025, Pops acquired 2,869 shares of common stock at $0 price.
• Following the reported transactions, Pops beneficially owns 34,480 shares of common stock.
• Pops also acquired 3,318 Restricted Stock Units (RSUs) on May 21, 2025, which will vest in full on May 21, 2026.
• Additionally, Pops disposed of 2,869 shares underlying fully vested RSUs on May 22, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, reflecting neutral sentiment. It simply reports transactions without expressing any positive or negative outlook.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, which is common in the biotechnology industry. These filings are monitored by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Richard F. Pops, Stock Transactions, Restricted Stock Units, Director, Beneficial Ownership